Moreover, the crosstalk between colorectal carcinoma cells and microenvironment-infiltrating immune cells induces NLRP3 inflammasome activation in macrophages and the blockage of NLRP3 signaling by NLRP3 antagonist, glibenclamide or caspase-1 antagonist, AC-YVAD-cmk, suppressed colorectal cancer cell migration, and liver metastasis [12]. This evidence concerns the gene NLRP3 and colorectal carcinoma.